Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
0.8604
-0.0404 (-4.48%)
At close: May 15, 2026, 4:00 PM EDT
0.8689
+0.0085 (0.99%)
After-hours: May 15, 2026, 4:10 PM EDT
Adagio Medical Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
80
Market Cap
19.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 602.00K | 302.00K | 100.67% |
| Dec 31, 2023 | 300.00K | 111.00K | 58.73% |
| Dec 31, 2022 | 189.00K | -81.00K | -30.00% |
| Dec 31, 2021 | 270.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 428.57M |
| IRIDEX | 52.68M |
| Myomo | 41.21M |
| Cytosorbents | 37.06M |
| Lifeward | 22.03M |
| Pulsenmore | 12.55M |
| Picard Medical | 4.94M |
| IceCure Medical | 3.57M |
ADGM News
- 4 days ago - Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress - Business Wire
- 17 days ago - Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference - Business Wire
- 20 days ago - Adagio Medical reports six-month results from Fulcrum-VT IDE trial - TheFly
- 20 days ago - Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System - Business Wire
- 4 weeks ago - Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference - Business Wire
- 4 weeks ago - Adagio Medical initiated with an Overweight at Piper Sandler - TheFly
- 5 weeks ago - Adagio Medical announces FDA granted IDE approval for FULCRUM-VT trial - TheFly
- 5 weeks ago - Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System - Business Wire